Alvarado-Miranda, A.; Lara-Medina, F.U.; Muñoz-Montaño, W.R.; Zinser-Sierra, J.W.; Galeana, P.A.C.; Garza, C.V.; Sanchez Benitez, D.; Limón Rodríguez, J.A.; Arce Salinas, C.H.; Guijosa, A.;
et al. Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Curr. Oncol. 2024, 31, 7177-7179.
https://doi.org/10.3390/curroncol31110529
AMA Style
Alvarado-Miranda A, Lara-Medina FU, Muñoz-Montaño WR, Zinser-Sierra JW, Galeana PAC, Garza CV, Sanchez Benitez D, Limón Rodríguez JA, Arce Salinas CH, Guijosa A,
et al. Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Current Oncology. 2024; 31(11):7177-7179.
https://doi.org/10.3390/curroncol31110529
Chicago/Turabian Style
Alvarado-Miranda, Alberto, Fernando Ulises Lara-Medina, Wendy R. Muñoz-Montaño, Juan W. Zinser-Sierra, Paula Anel Cabrera Galeana, Cynthia Villarreal Garza, Daniel Sanchez Benitez, Jesús Alberto Limón Rodríguez, Claudia Haydee Arce Salinas, Alberto Guijosa,
and et al. 2024. "Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110" Current Oncology 31, no. 11: 7177-7179.
https://doi.org/10.3390/curroncol31110529
APA Style
Alvarado-Miranda, A., Lara-Medina, F. U., Muñoz-Montaño, W. R., Zinser-Sierra, J. W., Galeana, P. A. C., Garza, C. V., Sanchez Benitez, D., Limón Rodríguez, J. A., Arce Salinas, C. H., Guijosa, A., & Arrieta, O.
(2024). Correction: Alvarado-Miranda et al. Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer. Curr. Oncol. 2023, 30, 6097–6110. Current Oncology, 31(11), 7177-7179.
https://doi.org/10.3390/curroncol31110529
